Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin effects on amygdala in PTSD
NCT01963078Phase 2Completed
- Start
- Apr 2013
- Primary completion
- Jan 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in post-traumatic stress disorder (PTSD) (4 arms). Primary endpoint: Change in Amygdala Activation - Oxy Minus Placebo at Day 2. Started Apr 2013; status: completed.
02
Drugs
oxytocin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT01963078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01963078.